|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||62.4928 - 63.0400|
|52 Week Range||57.9300 - 71.4200|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.56%|
Projprzem SA. (WSE:PJP) delivered an ROE of 10.70% over the past 12 months, which is an impressive feat relative to its industry average of 5.43% during the same period. WhileRead More...
While small-cap stocks, such as Projprzem SA. (WSE:PJP) with its market cap of ZŁ95.72M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
The US Bureau of Economic Analysis publishes a monthly report on US international trade in goods and services that details the changes in imports and exports. The latest report indicated that the goods and services deficit was $57.6 billion in February, an increase of $0.9 billion from $56.7 billion in January. The trade deficit is currently at a nine-year high, and this could be cited as one of the key reasons the Trump administration has taken steps to increase trade barriers.
Eli Lilly and Company (LLY) is a US pharmaceutical company with headquarters in Indianapolis, Indiana. The company specializes in products for both human health and animal health.
As we discussed earlier, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenue in 4Q17. Eli Lilly also surpassed analysts’ estimates for EPS and revenue for 2017, reporting EPS of $4.28 on revenue of ~$22.9 billion compared to the estimate of $4.22 on revenue of ~$22.7 billion for the year. In 1Q18, Wall Street analysts expect EPS of $1.14 on revenue of $5.5 billion for the company, a ~5.0% rise compared to 1Q17.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
Valeant Pharmaceuticals (VRX) operates through three segments: Bausch and Lomb (or the International segment), Branded Prescriptions, and US Diversified Products. This segment consists of Valeant’s US sales of pharmaceutical products, over the counter products, and medical devices, which primarily consist of ophthalmics, surgical, consumer products, and the sales of branded, generic, over-the-counter, and medical devices in Canada, Europe, Asia, Australia, New Zealand, Latin America, Africa, and the Middle East. With the sale of Dendreon in June 2017, Valeant exited its oncology business, which was a part of the Branded Prescriptions segment.
In his first State of the Union speech, President Trump didn’t have any surprises for the markets (SPY). At the annual State of the Union meeting, President Trump addressed a joint session of Congress. President Trump stayed away from any surprise statements that could have spooked the markets.
On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.
In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million,…...
The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.
In August 2017, JAZZ's Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Forteo is used for the treatment of osteoporosis. Forteo's sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.